Alpine Woods Capital Investors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alpine Woods Capital Investors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-18,780	Closed	-$2.44M	–	220
2021 Q3	$2.44M	Hold	18,780	–	–	0.26%	111
2021 Q2	$3.34M	Sell	18,780 -20	-0.1%	-$3.46K	0.35%	98
2021 Q1	$3.09M	Hold	18,800	–	–	0.34%	100
2020 Q4	$3.1M	Sell	18,800 -1,500	-7%	-$223K	0.38%	93
2020 Q3	$2.9M	Sell	20,300 -1,650	-8%	-$205K	0.44%	79
2020 Q2	$2.42M	Sell	21,950 -870	-4%	-$96.2K	0.47%	67
2020 Q1	$2.28M	Hold	22,820	–	–	0.51%	56
2019 Q4	$3.41M	Hold	22,820	–	–	0.65%	39
2019 Q3	$2.92M	Sell	22,820 -100	-0.4%	-$13.4K	0.54%	38
2019 Q2	$3.27M	Hold	22,920	–	–	0.68%	32
2019 Q1	$3.28M	Sell	22,920 -100	-0.4%	-$13K	0.71%	29
2018 Q4	$2.85M	Sell	23,020 -100	-0.4%	-$14.8K	0.69%	34
2018 Q3	$3.89M	Hold	23,120	–	–	0.8%	27
2018 Q2	$3.98M	Sell	23,120 -30	-0.1%	-$4.9K	0.87%	22
2018 Q1	$3.5M	Sell	23,150 -350	-1%	-$51.3K	0.19%	139
2017 Q4	$3.16M	Hold	23,500	–	–	0.16%	152
2017 Q3	$3.44M	Sell	23,500 -5,000	-18%	-$756K	0.18%	142
2017 Q2	$4.43M	Sell	28,500 -2,000	-7%	-$306K	0.24%	129
2017 Q1	$4.43M	Sell	30,500 -600	-2%	-$78.1K	0.24%	125
2016 Q4	$3.39M	Sell	31,100 -70	-0.2%	-$7.8K	0.19%	141
2016 Q3	$3.79M	Hold	31,170	–	–	0.21%	129
2016 Q2	$4.41M	Hold	31,170	–	–	0.26%	117
2016 Q1	$4.07M	Hold	31,170	–	–	0.24%	122
2015 Q4	$4.38M	Sell	31,170 -500	-2%	-$69.3K	0.24%	128
2015 Q3	$4.21M	Buy	31,670 +1,000	+3%	+$172K	0.23%	133
2015 Q2	$5.4M	Hold	30,670	–	–	0.28%	112
2015 Q1	$5.3M	Hold	30,670	–	–	0.27%	113
2014 Q4	$5.02M	Buy	30,670 +470	+2%	+$78K	0.26%	107
2014 Q3	$4.85M	Sell	30,200 -3,000	-9%	-$461K	0.26%	106
2014 Q2	$4.88K	Buy	33,200 +50	+0.2%	+$6.93K	0.13%	101
2014 Q1	$4.6M	Sell	33,150 -1,150	-3%	-$173K	0.25%	99
2013 Q4	$4.34M	Buy	34,300 +4,600	+15%	+$476K	0.25%	102
2013 Q3	$2.73M	Buy	29,700 +12,700	+75%	+$1.02M	0.17%	120
2013 Q2	$1.17M	Buy	+17,000	New	+$1.04M	0.07%	171

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alpine Woods Capital Investors's JAZZ Position: Q4 2021 in Review

Alpine Woods Capital Investors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 18,780 shares — an estimated $2.44M sold.

Alpine Woods Capital Investors first reported a position in JAZZ in Q2 2013 and held it in 34 quarters. The position peaked at $5.4M in Q2 2015. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Alpine Woods Capital Investors reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Alpine Woods Capital Investors sold 18,780 Jazz Pharmaceuticals shares in Q4 2021, an estimated $2.44M.
Alpine Woods Capital Investors first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 34 quarters.
Alpine Woods Capital Investors's Jazz Pharmaceuticals position peaked at $5.4M in Q2 2015.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Alpine Woods Capital Investors's 13F filing for Q4 2021, filed 3 Feb 2022.